Jan 28, 2008
Quintiles Transnational (Research Triangle Park, North Carolina) has completed a new investor partnership in which CEO Dennis Gillings and private investment firms Bain Capital and TPG Capital have become the lead investors.
Jan 22, 2008
GlaxoSmithKline has decided not to exercise its option to license Exelixis’s (San Francisco, California) kidney disease drug XL784 for further development and commercialisation.
Jan 16, 2008
Quintiles Transnational (Research Triangle Park, North Carolina) is to expand its global central laboratories and clinical development service (CDS) units in Beijing, China.
Jan 11, 2008
US private equity firm Genstar Capital (San Francisco, California) has completed its $797 million acquisition of PRA International (Reston, Virginia).
Jan 09, 2008
The US Food and Drug Administration has lifted its clinical hold on Vion Pharmaceuticals’ Phase III trial of its lead anti-cancer agent, Cloretazine (VNP40101M), in combination with Ara-C (cytarabine) in relapsed acute myelogenous leukaemia (AML).
Jan 08, 2008
Pfizer has started a dose-ranging Phase II clinical trial of PF-03187207 for the treatment of glaucoma in Japan.
Jan 05, 2008
US CRO Clinsys Clinical Research (Bedminster, New Jersey) and its French counterpart ITEC Services (Cenon, Bordeaux) have entered into a strategic alliance agreement.
Jan 02, 2008
PPD (Wilmington, North Carolina) has appointed Dr Philip Mathew as director of strategic development, to lead its Phase II-IV operations and expansion in India.
Dec 13, 2007
Sanofi-aventis officially opened its first Asian pharmaceutical development centre in Goa, India on December 3rd. The investment represents the company’s single largest in India to date.
Dec 10, 2007
Seattle Genetics (Bothell, Washington) has begun a Phase IIb clinical trial of its monoclonal antibody SGN-40 as an adjunct to second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).